Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

0
Player Avatar sujoypaul (< 20) Submitted: 5/4/2010 3:07:14 PM : Outperform Start Price: $2.69 NVAX Score: -65.19

BARDA contract, Mexico approval. Final stage of US FDA Phase III

Featured Broker Partners


Advertisement